These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31289316)

  • 21. Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms.
    Hao X; Xing W; Yuan J; Wang Y; Bai J; Bai J; Zhou Y
    Invest New Drugs; 2020 Jun; 38(3):610-620. PubMed ID: 31227936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Ruxolitinib on Immune Checkpoint Molecule Expression in JAK2 V617F-Positive Cells.
    Fu J; Cheng Z; Zhang L; Wen X; Hao J
    Clin Lab; 2024 Oct; 70(10):. PubMed ID: 39382932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aurora kinase targeting in lung cancer reduces KRAS-induced transformation.
    Dos Santos EO; Carneiro-Lobo TC; Aoki MN; Levantini E; Bassères DS
    Mol Cancer; 2016 Feb; 15():12. PubMed ID: 26842935
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aberrant let7a/HMGA2 signaling activity with unique clinical phenotype in
    Chen CC; You JY; Lung J; Huang CE; Chen YY; Leu YW; Ho HY; Li CP; Lu CH; Lee KD; Hsu CC; Gau JP
    Haematologica; 2017 Mar; 102(3):509-518. PubMed ID: 28057739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reversine induces cell cycle arrest and apoptosis via upregulation of the Fas and DR5 signaling pathways in human colorectal cancer cells.
    Park YL; Ha SY; Park SY; Choi JH; Jung MW; Myung DS; Kim HS; Joo YE
    Int J Oncol; 2019 May; 54(5):1875-1883. PubMed ID: 30864676
    [TBL] [Abstract][Full Text] [Related]  

  • 26. JAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation.
    Oku S; Takenaka K; Kuriyama T; Shide K; Kumano T; Kikushige Y; Urata S; Yamauchi T; Iwamoto C; Shimoda HK; Miyamoto T; Nagafuji K; Kishimoto J; Shimoda K; Akashi K
    Br J Haematol; 2010 Aug; 150(3):334-44. PubMed ID: 20553273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiogenesis in JAK2 V617F positive myeloproliferative neoplasms and ruxolitinib decrease VEGF, HIF-1 enesis in JAK2 V617F positive cells.
    Cheng Z; Fu J; Liu G; Zhang L; Xu Q; Wang SY
    Leuk Lymphoma; 2018 Jan; 59(1):196-203. PubMed ID: 28554272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis.
    Winter PS; Sarosiek KA; Lin KH; Meggendorfer M; Schnittger S; Letai A; Wood KC
    Sci Signal; 2014 Dec; 7(357):ra122. PubMed ID: 25538080
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of ruxolitinib with ABT-737 exhibits synergistic effects in cells carrying concurrent JAK2
    Yuan J; Song J; Chen C; Lv X; Bai J; Yang J; Zhou Y
    Invest New Drugs; 2022 Dec; 40(6):1194-1205. PubMed ID: 36044173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2
    Courdy C; Platteeuw L; Ducau C; De Araujo I; Boet E; Sahal A; Saland E; Edmond V; Tavitian S; Bertoli S; Cougoul P; Granat F; Poillet L; Marty C; Plo I; Sarry JE; Manenti S; Mansat-De Mas V; Joffre C
    Blood Cancer J; 2023 Jul; 13(1):106. PubMed ID: 37423955
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
    Hobbs GS; Rozelle S; Mullally A
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms.
    Sharma V; Wright KL; Epling-Burnette PK; Reuther GW
    Front Immunol; 2020; 11():604142. PubMed ID: 33329600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.
    Gao SM; Chen CQ; Wang LY; Hong LL; Wu JB; Dong PH; Yu FJ
    Exp Hematol; 2013 Mar; 41(3):261-70.e4. PubMed ID: 23111066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
    Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
    FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IL-6 stimulation of DNA replication is JAK1/2 mediated in cross-talk with hyperactivated ERK1/2 signaling.
    Subotički T; Mitrović Ajtić O; Beleslin-Čokić BB; Bjelica S; Djikić D; Diklić M; Leković D; Gotić M; Santibanez JF; Noguchi CT; Čokić VP
    Cell Biol Int; 2019 Feb; 43(2):192-206. PubMed ID: 30571852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: a new therapeutic target?
    Ramos TL; Sánchez-Abarca LI; Redondo A; Hernández-Hernández Á; Almeida AM; Puig N; Rodríguez C; Ortega R; Preciado S; Rico A; Muntión S; Porras JRG; Del Cañizo C; Sánchez-Guijo F
    Oncotarget; 2017 Apr; 8(17):28187-28202. PubMed ID: 28390197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tyrosine-phosphorylated SOCS3 negatively regulates cellular transformation mediated by the myeloproliferative neoplasm-associated JAK2 V617F mutant.
    Funakoshi-Tago M; Tsuruya R; Ueda F; Ishihara A; Kasahara T; Tamura H; Tago K
    Cytokine; 2019 Nov; 123():154753. PubMed ID: 31255914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structural basis of reversine selectivity in inhibiting Mps1 more potently than aurora B kinase.
    Hiruma Y; Koch A; Dharadhar S; Joosten RP; Perrakis A
    Proteins; 2016 Dec; 84(12):1761-1766. PubMed ID: 27699881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic Cytotoxic Effect of Busulfan and the PARP Inhibitor Veliparib in Myeloproliferative Neoplasms.
    Patel PR; Senyuk V; Rodriguez NS; Oh AL; Bonetti E; Mahmud D; Barosi G; Mahmud N; Rondelli D
    Biol Blood Marrow Transplant; 2019 May; 25(5):855-860. PubMed ID: 30615982
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells.
    Amaru Calzada A; Todoerti K; Donadoni L; Pellicioli A; Tuana G; Gatta R; Neri A; Finazzi G; Mantovani R; Rambaldi A; Introna M; Lombardi L; Golay J;
    Exp Hematol; 2012 Aug; 40(8):634-45.e10. PubMed ID: 22579713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.